CHMP gives Lantus all clear for cancer
This article was originally published in Scrip
Executive Summary
The EMA's committee for medicinal products for human use (CHMP) has returned an "all clear" verdict for products containing Sanofi's insulin glargine, which had been under review for a possible increased risk of cancer.